Orbis serves as the intelligence layer connecting ICON's clinical, operational, and enterprise data. The Microsoft ...
AI in clinical trials holds great promise for the entire drug development lifecycle. However, any new technology should ...
Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...
An expert panel has proposed 28 recommendations for the design and conduct of clinical trials for alcohol use disorders and alcohol-associated liver disease. This field has a scarcity of clinical ...
Clinical trial design decisions impact costs, access, and evidence gaps, with breast cancer as the most studied disease globally. The US leads in trial activity, with China showing rapid growth, ...
Digital patient profiles and real-world data enhance oncology trial design, patient recruitment, and reduce trial failure risks. Phesi's platform aligns trial designs with real-world data, minimizing ...
New FDA guidance on the use of Bayesian statistics signals a broader shift in accommodating more flexible clinical trial ...
Clinical trial statistics underlie the central decision-making process for whether a therapeutic approach can enter the clinic, but the nuances of this field may not be widely understood. Furthermore, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results